UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE

Registered charity 1044013 · accounts filings on the Charity Commission register · also known as PATHOLOGY QUALITY ASSESSMENT, UK NEQAS, UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESMENT SERVICE

The objects of the charity shall be to advance education and promote the preservation of good health by providing or securing the provision of external quality assessment services for clinical laboratories.

Objects

THE OBJECTS OF THE CHARITY SHALL BE TO ADVANCE EDUCATION AND PROMOTE THE PRESERVATION OF GOOD HEALTH BY PROVIDING OR SECURING THE PROVISION OF EXTERNAL QUALITY ASSESSMENT SERVICES FOR CLINICAL LABORATORIES

Area of benefit: NOT DEFINED

The charity’s charitable objects and area of benefit, quoted from its governing document as held on the Charity Commission register.

Causes: Education/training · The Advancement Of Health Or Saving Of Lives · website · Get email alerts

Latest income
£277k
Latest spending
£261k
Registered
1995
Accounts read
FY2025

Financial health, per its FY2025 accounts

The accounts state that the charity and its trading subsidiary combined had a surplus of £15,581 for the year ended 31 March 2025, with total unrestricted reserves of £195,942. The trustees report that these reserves represent 88% of the group's consolidated operating costs, exceeding the stated policy target of 60%. The financial statements are prepared on a going concern basis, with the trustees expressing reasonable expectation of adequate resources for the foreseeable future.

Automated summary of the FY2025 accounts; the evidenced findings below carry the verbatim passages.

What the accounts disclose

Reserves policy: 60% of one year's operating costs (held: £196k)
“the charity maintains a high level of unrestricted reserves, agreed upon by the trustees, equivalent to 60% of one year's operating costs.” — page 10
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Payment to QED Haematology Limited for services of trustee Dr B De la Salle
“During the year, the company paid £20,000 (2024: £20,000) to QED Haematology Limited for the services of Mrs B De la Salle, trustee.” — page 23
“During the year, sales totalling £13,396 (2024: £11,060) were made to Labxcell Limited, a company which trustees C Hodgson and L Whitby were also directors of.” — page 23
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Sales to Labxcell Limited, a company where trustees C Hodgson and L Whitby are directors
“During the year, the company paid £20,000 (2024: £20,000) to QED Haematology Limited for the services of Mrs B De la Salle, trustee.” — page 23
“During the year, sales totalling £13,396 (2024: £11,060) were made to Labxcell Limited, a company which trustees C Hodgson and L Whitby were also directors of.” — page 23
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Sales to External Quality Assessment Services for Cancer Diagnostics C.I.C., a company where trustees L Whitby, S Parry and director A Dodson are directors
“During the year, the company paid £20,000 (2024: £20,000) to QED Haematology Limited for the services of Mrs B De la Salle, trustee.” — page 23
“During the year, sales totalling £13,396 (2024: £11,060) were made to Labxcell Limited, a company which trustees C Hodgson and L Whitby were also directors of.” — page 23
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Reimbursement of expenses to trustees
“During the year, the company paid £20,000 (2024: £20,000) to QED Haematology Limited for the services of Mrs B De la Salle, trustee.” — page 23
“During the year, sales totalling £13,396 (2024: £11,060) were made to Labxcell Limited, a company which trustees C Hodgson and L Whitby were also directors of.” — page 23
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Income from member schemes where trustees are employees
“During the year, the company paid £20,000 (2024: £20,000) to QED Haematology Limited for the services of Mrs B De la Salle, trustee.” — page 23
“During the year, sales totalling £13,396 (2024: £11,060) were made to Labxcell Limited, a company which trustees C Hodgson and L Whitby were also directors of.” — page 23
Per its FY2025 accounts as filed with the Charity Commission.
Trading subsidiary: Pathology Quality Assessment Limited
“The financial statements consolidate the accounts of United Kingdom National External Quality Assessment Service and its wholly owned subsidiary, Pathology Quality Assessment Limited.” — page 18
Per its FY2025 accounts as filed with the Charity Commission.

Accounts independently examined (not a full audit). Discloses 5 of 6 completeness components.

Policies the charity declares

In its annual return the charity told the Commission that it has the policies listed below. This is self-declared: it is not verified by the Commission or by this site, and it is not evidence of how a policy works in practice.

Public-sector contracts awarded

From the official Contracts Finder and Find a Tender notices (supplier matched by exact registered name). Contract income is distinct from grants.

BuyerContractAwardedValue
NHS EnglandExternal Quality Assessment (EQA) Service——

Trustees · trustee networks

Trustee list from the Charity Commission register (current, not historical).

Operates in: Scotland

Income and spending

Financial year endIncomeSpending
31/03/2025£277k£261k
31/03/2024£273k£295k
31/03/2023£251k£241k
31/03/2022£227k£214k
31/03/2021£234k£201k

Common questions

Is UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE financially healthy?

Per its FY2025 accounts: The accounts state that the charity and its trading subsidiary combined had a surplus of £15,581 for the year ended 31 March 2025, with total unrestricted reserves of £195,942. The trustees report that these reserves represent 88% of the group's consolidated operating costs, exceeding the stated policy target of 60%. The financial statements are prepared on a going concern basis, with the trustees expressing reasonable expectation of adequate resources for the foreseeable future. Its FY2025 accounts were independently examined.